AstraZeneca plans to shutter lab, ax staffers

AstraZeneca ($AZN) is shuttering a lab in Devon, U.K., saying that it will now outsource work done to test the environment impact of drugs. The pharma giant has been undergoing a major restructuring, its third reorganization in recent years. The lab employs 71 people. An AstraZeneca exec says they plan to "support" the workers in coming months and would prefer to see the facility remain open. Release

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.